List of Excipients in Branded Drug BANZEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eisai Inc	BANZEL	rufinamide	62856-582	CELLULOSE, MICROCRYSTALLINE
Eisai Inc	BANZEL	rufinamide	62856-582	CROSCARMELLOSE SODIUM
Eisai Inc	BANZEL	rufinamide	62856-582	FERRIC OXIDE RED
Eisai Inc	BANZEL	rufinamide	62856-582	HYPROMELLOSE 2208
Eisai Inc	BANZEL	rufinamide	62856-582	HYPROMELLOSE 2910
Eisai Inc	BANZEL	rufinamide	62856-582	LACTOSE MONOHYDRATE

BANZEL Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

BANZEL is the U.S. brand for rufinamide, an oral antiseizure drug approved as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged 1 year and older. Its commercial formulation set includes immediate-release tablets and an oral suspension. The strongest excipient opportunities are pediatric taste masking, suspension stability, dose-measurement accuracy, alternative dosage forms, and geographic adaptation for markets with different preservative or sugar requirements.

Rufinamide is a small molecule, so biosimilar risk does not apply. The principal competitive route is generic substitution through ANDA approval, while differentiated formulations may use a 505(b)(2) strategy or non-U.S. regulatory pathways.

What formulations does BANZEL use?

BANZEL is supplied as immediate-release film-coated tablets and an oral suspension containing 40 mg/mL rufinamide. The suspension is particularly important because Lennox-Gastaut syndrome affects young children and patients who may have difficulty swallowing tablets.

Product	Strengths	Route	Commercial role
BANZEL tablets	200 mg, 400 mg	Oral	Main solid-dose product for patients able to swallow tablets
BANZEL oral suspension	40 mg/mL	Oral	Pediatric and dysphagia-focused formulation
Rufinamide generic tablets	Multiple strengths depending on manufacturer	Oral	ANDA-based substitution opportunity
Rufinamide generic suspension	40 mg/mL or equivalent approved presentation	Oral	Direct competition for pediatric use

The FDA label instructs patients and caregivers to shake the suspension before use and measure doses with the supplied oral syringe. The label also requires administration with food, a factor that affects bioavailability, product positioning, and formulation development.[1]

What excipients are used in BANZEL tablets?

The BANZEL tablet formulation uses conventional direct-compression and film-coating excipients. The inactive ingredients listed in the U.S. prescribing information include:

• Colloidal silicon dioxide
• Corn starch
• Hypromellose
• Lactose monohydrate
• Magnesium stearate
• Microcrystalline cellulose
• Sodium lauryl sulfate

These excipients support powder flow, tablet compression, lubrication, disintegration, coating performance, and wetting. Lactose and microcrystalline cellulose provide the principal diluent system. Sodium lauryl sulfate can improve wetting of the poorly water-soluble drug but may create tolerability, taste, or regulatory-sensitivity issues in pediatric products.

Tablet excipient strategy

A generic tablet developer has several formulation options:

1. Maintain a close qualitative and quantitative excipient profile to reduce bioequivalence and formulation risk.
2. Replace lactose for patients with lactose intolerance or to simplify global registration.
3. Reduce or eliminate sodium lauryl sulfate if dissolution can be maintained with alternative wetting agents.
4. Use a co-processed filler for improved content uniformity at lower drug loading.
5. Develop an orally disintegrating tablet or mini-tablet for pediatric patients who cannot swallow conventional tablets.

The most commercially defensible tablet innovation would combine rapid disintegration, acceptable taste, and a compact dosage form. A simple excipient substitution is less likely to support premium pricing unless it provides a measurable benefit, such as improved dissolution with food variability or improved suitability for younger patients.

What excipients are used in BANZEL oral suspension?

The BANZEL oral suspension uses a multidimensional excipient system for wetting, viscosity control, sweetening, flavor, preservation, and chemical stability. The FDA labeling identifies inactive ingredients including:

• Citric acid anhydrous
• Hypromellose
• Methylparaben sodium
• Microcrystalline cellulose
• Polysorbate 80
• Potassium sorbate
• Sodium benzoate
• Sodium saccharin
• Sorbitol
• Sucralose
• Strawberry flavor
• Purified water

The formulation uses multiple preservation agents and sweeteners. Hypromellose and microcrystalline cellulose contribute to suspension structure and redispersibility. Polysorbate 80 supports wetting and dispersion. Sorbitol, sucralose, sodium saccharin, and strawberry flavor address palatability. Citric acid controls pH, while methylparaben sodium, potassium sorbate, and sodium benzoate provide antimicrobial protection.[1]

Suspension development priorities

The formulation presents several development targets:

Development target	Current formulation issue	Commercial opportunity
Palatability	Rufinamide may require substantial sweetener and flavor support	Better taste masking and lower sweetener burden
Redispersibility	Suspensions can settle during storage	Improved rheology and dose uniformity
Preservatives	Multiple preservatives may limit positioning in sensitive pediatric populations	Preservative-free or reduced-preservative product
Sugar alcohols	Sorbitol can cause gastrointestinal effects at higher exposure	Low-sorbitol or sorbitol-free formulation
Dose accuracy	Suspension dosing depends on shaking and syringe technique	Unit-dose sachets, premeasured syringes, or improved suspension behavior
Storage	Liquid products face microbial and chemical stability demands	Longer in-use stability and broader temperature tolerance
Flavor	Strawberry flavor may not suit all markets or patients	Alternate flavors or neutral taste-masked formulation

How strong is the excipient opportunity for rufinamide?

The strongest opportunity is a pediatric liquid with improved palatability and dosing reliability. The existing suspension already addresses pediatric administration, so a new entrant must show a practical advantage rather than merely reproduce the reference formulation.

Potential differentiation includes:

• A smaller administration volume through higher concentration, subject to safety and dosing accuracy controls.
• A taste-masked formulation with less reliance on saccharin, sucralose, sorbitol, or multiple preservatives.
• A ready-to-use suspension with improved redispersibility.
• A dry powder for reconstitution that reduces shipping weight and improves shelf life.
• Unit-dose oral syringes for home, hospital, and institutional use.
• A low-volume formulation for patients receiving multiple antiseizure medicines.
• An orally disintegrating mini-tablet that can be dispersed in a small amount of soft food or liquid.

A higher concentration is commercially attractive but creates a dosing-risk tradeoff. Rufinamide dosing is weight-based in pediatric patients, so small measurement errors can have a larger clinical effect when the formulation is concentrated.

What generic entry risks exist for BANZEL?

Rufinamide is a small-molecule drug and is subject to generic substitution rather than biosimilar competition. The principal generic entry risks are:

1. Direct ANDA competition for 200 mg and 400 mg tablets.
2. Generic oral suspension competition in pediatric markets.
3. Hospital and payer formulary substitution.
4. Price erosion after multiple approved manufacturers enter.
5. Reference-product supply interruptions that encourage pharmacy switching.
6. Formulation workarounds using different excipients while maintaining bioequivalence.

The tablet market is generally more exposed to rapid price erosion because solid oral dosage forms are easier to manufacture and scale. The suspension market has higher technical barriers because developers must demonstrate dose uniformity, microbial quality, preservative effectiveness, physical stability, and acceptable bioequivalence or comparative performance.

When did BANZEL lose exclusivity?

BANZEL received FDA approval in November 2008 for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. The product also received orphan-drug exclusivity, which provided seven years of market protection for the approved orphan indication, subject to the scope of that designation.[2]

The orphan exclusivity period would have ended in 2015, excluding any applicable pediatric extension. Pediatric exclusivity can add six months to qualifying regulatory exclusivity or patent terms, but it does not create a new independent seven-year orphan period.[3]

Regulatory protection	Relevant timing	Commercial effect
FDA approval	November 2008	Established the reference product
Orphan exclusivity	Approximately seven years from approval	Protected the approved orphan indication
Pediatric exclusivity	Six-month extension if granted	Could extend qualifying exclusivity or patent terms
Current competition	Post-exclusivity	Generic and reformulation strategies become central

Patent expiration must be assessed against the current FDA Orange Book and relevant national registers. The active ingredient’s original composition-of-matter protection is no longer the principal commercial barrier. Any remaining protection would more likely concern formulation, method of use, manufacturing, or later-filed patents rather than basic rufinamide composition.

What patents protect BANZEL formulations?

Formulation protection for BANZEL may cover:

• Specific suspension compositions
• Particle-size distribution
• Stabilizer or suspending-agent combinations
• Taste-masking systems
• Preservative combinations
• Liquid concentration and pH
• Manufacturing processes
• Dosing devices or administration systems
• Methods of treating Lennox-Gastaut syndrome

For U.S. generic planning, the relevant legal review includes the Orange Book patent listing, FDA-approved labeling, ANDA litigation records, and any later-issued patents associated with rufinamide formulations. A formulation patent has greater commercial value when it is listed for the reference product and maps directly to the marketed dosage form. Unlisted formulation patents can still create litigation risk but may not trigger the same ANDA certification consequences as an Orange Book-listed patent.

The practical strength of an excipient patent depends on claim breadth. A claim limited to a narrow preservative ratio or one flavor system may be easy to design around. Claims directed to a specific concentration, stability profile, particle-size range, or clinically meaningful dosing advantage may create a more significant barrier.

What is the FDA regulatory status of BANZEL?

BANZEL is an FDA-approved prescription product. The approved U.S. dosage forms are immediate-release tablets and an oral suspension. The approved indication is adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged 1 year and older.[1]

A conventional generic tablet normally proceeds through an ANDA with pharmaceutical equivalence and bioequivalence requirements. A materially different liquid, concentrated suspension, orally disintegrating product, or altered administration method may require a 505(b)(2) application if the sponsor relies partly on the reference product while introducing a clinically or pharmaceutically meaningful difference.[4]

Excipient changes can affect the regulatory route when they alter:

• Absorption or food effect
• Dose delivery
• Local tolerability
• Pediatric acceptability
• Product stability
• Administration through feeding tubes
• Preservative exposure
• In-use microbial control

Which companies are challenging BANZEL commercially?

Competition is likely to come from generic pharmaceutical companies with established oral-solid and pediatric-liquid manufacturing capabilities. The competitive field includes:

Competitor type	Likely product	Primary advantage
Large generic manufacturer	Rufinamide tablets	Scale, contracting, low cost
Specialty generic manufacturer	Oral suspension	Pediatric formulation capability
Contract development and manufacturing organization	Reformulated liquid or mini-tablet	Speed and formulation expertise
Branded specialty company	Improved pediatric formulation	Differentiation and specialty-pharmacy access
Regional manufacturer	Local tablet or liquid	Country-specific regulatory and distribution reach

Public FDA approval databases and the Orange Book should be used to identify the current approved ANDA holders and patent certifications. Market share will depend on payer contracts, pharmacy substitution, supply continuity, and whether the generic is available in both tablet and suspension forms.

What licensing deals could support a BANZEL reformulation?

A reformulation program can use several licensing structures:

• License a taste-masking technology for rufinamide.
• License a pediatric suspension platform.
• Partner with a specialty pharmaceutical company with epilepsy distribution.
• Use a contract manufacturer with validated liquid and oral-solid capacity.
• License a unit-dose syringe or dosing-device platform.
• Acquire regional rights for a reformulated product.

The most valuable partnership would combine formulation IP with regulatory and commercial infrastructure. An excipient technology without manufacturing scale or pediatric distribution may have limited value because the reference product already has a liquid dosage form.

How does BANZEL compare with competing antiseizure drugs?

BANZEL competes in a narrow orphan epilepsy market rather than across the full antiseizure-drug category.

Drug	Active ingredient	Pediatric liquid availability	Key commercial consideration
BANZEL	Rufinamide	Yes	Lennox-Gastaut syndrome adjunctive therapy
Epidiolex	Cannabidiol	Yes	Different mechanism and controlled-substance considerations
ONFI	Clobazam	Yes	Sedation, controlled-substance status, and LGS use
Depakote	Divalproex sodium	Yes	Broad seizure use but significant safety monitoring
Lamictal	Lamotrigine	Dispersible/chewable options	Broader epilepsy indications and titration requirements
Topamax	Topiramate	Sprinkle capsules and liquid alternatives	Broad pediatric use and established generic competition

Rufinamide’s formulation opportunity is strongest where clinicians prioritize a liquid product specifically for LGS patients, while the drug’s commercial weakness is its narrow indication and existing generic exposure.

What revenue exposure does the BANZEL formulation strategy create?

Revenue exposure is concentrated in three areas:

1. Pediatric and caregiver adherence.
2. Specialty-pharmacy and hospital procurement.
3. Geographic markets where the reference liquid is unavailable or difficult to supply.

A conventional generic tablet has limited pricing power after multiple entrants. A differentiated suspension can preserve margin through improved administration, reduced preservative exposure, better storage, or device integration. The opportunity is greater in markets where caregivers administer weight-based doses several times daily and where accurate dosing affects adherence.

A reformulated product should be evaluated against four commercial thresholds:

• Incremental manufacturing cost per dose
• Regulatory cost and time
• Reimbursement or substitution risk
• Clinical value recognized by caregivers, prescribers, and payers

What manufacturing and IP barriers affect rufinamide products?

Manufacturing barriers are moderate for tablets and higher for liquids. Tablet production requires control of content uniformity, dissolution, coating, and physical stability. Suspension manufacturing requires additional control of particle dispersion, sedimentation, redispersibility, viscosity, preservative effectiveness, microbial limits, and container-closure performance.

The most defensible manufacturing IP may involve:

• Controlled particle engineering
• High-solids suspension processing
• Aseptic or low-bioburden manufacturing
• Preservative-free multidose packaging
• In-line dose uniformity controls
• Syringe-compatible container systems
• Dry-powder reconstitution with validated stability

Geographic expansion requires separate review of excipient acceptability, flavor regulations, preservative limits, local pediatric dosing conventions, packaging standards, and registration requirements. A formulation that uses sodium benzoate, methylparaben, sorbitol, or specific flavor components may require market-specific assessment.

Key Takeaways

• BANZEL is rufinamide, an FDA-approved adjunctive treatment for Lennox-Gastaut syndrome.
• The marketed formulation set includes immediate-release tablets and a 40 mg/mL oral suspension.
• The suspension uses hypromellose, microcrystalline cellulose, polysorbate 80, multiple preservatives, sweeteners, and strawberry flavor.
• The highest-value excipient opportunity is an improved pediatric liquid with better taste, redispersibility, dosing accuracy, or preservative profile.
• Rufinamide faces generic rather than biosimilar competition.
• Tablet generic entry is technically straightforward; suspension entry has greater formulation and manufacturing barriers.
• Orphan exclusivity began with the 2008 approval and would have expired approximately seven years later, subject to any pediatric extension.
• Current commercial protection should be assessed through Orange Book listings, formulation patents, method-of-use patents, and ANDA litigation records.
• A differentiated liquid, mini-tablet, dry powder, or dosing-device combination could support a 505(b)(2) or specialty-product strategy.
• Licensing value is highest when excipient IP is paired with pediatric regulatory expertise, scalable manufacturing, and epilepsy-focused distribution.

FAQs About BANZEL Excipients and Commercial Strategy

Can rufinamide be formulated without preservatives?

Yes, but a preservative-free multidose liquid would require an alternative microbial-control strategy, such as unit-dose packaging, aseptic manufacturing, or a validated container-closure system.

Is BANZEL suitable for an orally disintegrating tablet?

Rufinamide could be evaluated in an orally disintegrating tablet or mini-tablet, but taste masking, dose loading, mechanical strength, and food-effect performance would be central development issues.

Does BANZEL contain lactose?

The BANZEL tablet formulation lists lactose monohydrate as an inactive ingredient. The oral suspension uses a different excipient system and does not rely on lactose as the principal diluent.[1]

Is there biosimilar risk for BANZEL?

No. Rufinamide is a chemically synthesized small molecule. Competitive products are generics or reformulated small-molecule products, not biosimilars.

What is the most attractive commercial dosage form for a new rufinamide product?

A pediatric oral suspension with improved taste masking, low administration volume, reliable redispersion, and a differentiated dosing device offers the clearest opportunity. A conventional tablet would face stronger price competition.

References

1. U.S. Food and Drug Administration. (2024). BANZEL (rufinamide) prescribing information. Eisai Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals database. https://www.accessdata.fda.gov/scripts/op始
3. U.S. Food and Drug Administration. (n.d.). Pediatric exclusivity. https://www.fda.gov/drugs/development-resources/pediatric-exclusivity
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book